-+ 0.00%
-+ 0.00%
-+ 0.00%

X4 Pharmaceuticals corrects director nominee name in amended 8-K filing

PUBT·05/13/2026 20:58:27
Listen to the news
X4 Pharmaceuticals corrects director nominee name in amended 8-K filing
  • X4 Pharmaceuticals filed an amended Form 8-K to correct a typographical error in its prior report on results of May 11, 2026 annual meeting.
  • Original filing mistakenly identified Michael S. Wyzga as a Class III director nominee.
  • Amendment replaces that name with Murray W. Stewart, M.D., reflecting Class III directors elected to serve through 2029 annual meeting.
  • Filing stated no other disclosures in original report were changed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001501697-26-000051), on May 13, 2026, and is solely responsible for the information contained therein.